Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($27.74); post-transaction worth based connected April 9, 2026 marketplace adjacent (using $27.07 per share).

• What information of Modig's involvement was affected by this transaction?
  This merchantability accounted for 14.11% of Modig's nonstop presumption but lone 2.09% of his full Pharvaris holdings, fixed the important indirect involvement retained done Schoodif Management BV.

• Did the transaction impact immoderate derivative securities oregon indirect holdings?
  No derivative securities oregon indirect shares were transacted; each 23,333 shares sold were held straight anterior to the disposition.

• How does this enactment acceptable wrong the discourse of Modig's caller trading and disposable capacity?
  With nonstop holdings reduced to 142,084 shares post-sale and indirect holdings unchanged, the transaction reflects regular Rule 10b5-1 liquidity absorption and a shrinking disposable nonstop stock basal for further sales.

• How does the merchantability terms comparison to caller marketplace levels?
  The weighted mean merchantability terms of astir $27.74 per stock was somewhat supra the latest closing terms of $26.63 arsenic of April 10, 2026.

* 1-year show calculated utilizing April 9th, 2026 arsenic the notation date.

• Pharvaris N.V. develops oral therapies targeting hereditary angioedema (HAE), including PHA121, PHVS416 (on-demand brushed capsule), and PHVS719 (prophylactic extended-release tablet), with products successful assorted phases of objective trials.

• The institution operates a clinical-stage biopharmaceutical model, focusing connected research, development, and aboriginal commercialization of proprietary small-molecule drugs for uncommon diseases.

Pharvaris N.V. is simply a Leiden-based biotechnology institution specializing successful the improvement of oral therapies for uncommon diseases, with a superior absorption connected hereditary angioedema.

The institution leverages its expertise successful small-molecule cause find to beforehand a pipeline of differentiated treatments targeting important unmet aesculapian needs. Its strategy centers connected objective innovation and planetary marketplace entree to found a competitory presumption successful the uncommon illness therapeutics landscape.